相似文献
1
In vitro antifungal susceptibility and molecular characterization of clinical isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum.
Antimicrob Agents Chemother. 2008 Jun;52(6):2228-31. doi: 10.1128/AAC.00176-08. Epub 2008 Apr 7.
2
Less-frequent Fusarium species of clinical interest: correlation between morphological and molecular identification and antifungal susceptibility.
J Clin Microbiol. 2009 May;47(5):1463-8. doi: 10.1128/JCM.02467-08. Epub 2009 Mar 25.
3
Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy.
Antimicrob Agents Chemother. 2008 Jul;52(7):2683-5. doi: 10.1128/AAC.00272-08. Epub 2008 Apr 28.
4
Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods.
J Antimicrob Chemother. 2008 Apr;61(4):805-9. doi: 10.1093/jac/dkn022. Epub 2008 Feb 8.
5
Phylogenetic Diversity and In Vitro Susceptibility Profiles of Human Pathogenic Members of the Fusarium fujikuroi Species Complex Isolated from South India.
Mycopathologia. 2018 Jun;183(3):529-540. doi: 10.1007/s11046-018-0248-7. Epub 2018 Feb 14.
6
High genetic diversity and poor in vitro response to antifungals of clinical strains of Fusarium oxysporum.
J Antimicrob Chemother. 2009 Jun;63(6):1152-5. doi: 10.1093/jac/dkp095. Epub 2009 Mar 24.
7
Fusarium keratitis in South India: causative agents, their antifungal susceptibilities and a rapid identification method for the Fusarium solani species complex.
Mycoses. 2013 Sep;56(5):501-11. doi: 10.1111/myc.12062. Epub 2013 Feb 26.
8
Susceptibility of clinical isolates of Fusarium to antifungal drugs.
Mycoses. 1996 Jan-Feb;39(1-2):37-40. doi: 10.1111/j.1439-0507.1996.tb00081.x.
9
In vitro interactions of licensed and novel antifungal drugs against Fusarium spp.
Diagn Microbiol Infect Dis. 2004 Jan;48(1):69-71. doi: 10.1016/j.diagmicrobio.2003.09.003.
10
Keratitis by Fusarium temperatum, a novel opportunist.
BMC Infect Dis. 2014 Nov 12;14:588. doi: 10.1186/s12879-014-0588-y.
引用本文的文献
1
Genomic Insights into Diversity: The Genome of Two Clinical Isolates and Their Demethylase Inhibitor Fungicides Susceptibility.
Pathogens. 2024 Dec 3;13(12):1062. doi: 10.3390/pathogens13121062.
2
An updated list of eumycetoma causative agents and their differences in grain formation and treatment response.
Clin Microbiol Rev. 2024 Jun 13;37(2):e0003423. doi: 10.1128/cmr.00034-23. Epub 2024 May 1.
3
from Diseased Bananas and Human Patients: Susceptibility to Fungicides Used in Clinical and Agricultural Settings.
J Fungi (Basel). 2021 Sep 21;7(9):784. doi: 10.3390/jof7090784.
4
Case Report: Successful Management of Refractory Keratomycosis in an Alpaca Using Penetrating Keratoplasty and Combination Antifungal Therapy (Caspofungin 0.5% and Terbinafine 1%).
Front Vet Sci. 2021 Mar 11;8:644074. doi: 10.3389/fvets.2021.644074. eCollection 2021.
5
Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species.
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.00009-18. Print 2018 May.
6
Antifungal Susceptibility Testing of Fusarium: A Practical Approach.
J Fungi (Basel). 2017 Apr 26;3(2):19. doi: 10.3390/jof3020019.
7
Comparative Evaluation of Etest, EUCAST, and CLSI Methods for Amphotericin B, Voriconazole, and Posaconazole against Clinically Relevant Fusarium Species.
Antimicrob Agents Chemother. 2016 Dec 27;61(1). doi: 10.1128/AAC.01671-16. Print 2017 Jan.
8
Invasive Fusariosis in the Voriconazole Era: Single-Center 13-Year Experience.
Open Forum Infect Dis. 2015 Jul 4;2(3):ofv099. doi: 10.1093/ofid/ofv099. eCollection 2015 Sep.
9
Use of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of molds of the Fusarium genus.
J Clin Microbiol. 2015 Feb;53(2):465-76. doi: 10.1128/JCM.02213-14. Epub 2014 Nov 19.
10
Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment.
Eur J Clin Microbiol Infect Dis. 2013 Dec;32(12):1491-500. doi: 10.1007/s10096-013-1924-7. Epub 2013 Aug 11.
本文引用的文献
1
Cryptic species in Stachybotrys chartarum.
Mycologia. 2002 Sep-Oct;94(5):814-22.
2
Fusarium infections in immunocompromised patients.
Clin Microbiol Rev. 2007 Oct;20(4):695-704. doi: 10.1128/CMR.00014-07.
3
Phylogenetic diversity and microsphere array-based genotyping of human pathogenic Fusaria, including isolates from the multistate contact lens-associated U.S. keratitis outbreaks of 2005 and 2006.
J Clin Microbiol. 2007 Jul;45(7):2235-48. doi: 10.1128/JCM.00533-07. Epub 2007 May 16.
4
Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex.
Antimicrob Agents Chemother. 2007 Apr;51(4):1500-3. doi: 10.1128/AAC.01618-06. Epub 2007 Jan 12.
5
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions.
Clin Infect Dis. 2006 May 15;42(10):1398-403. doi: 10.1086/503425. Epub 2006 Apr 11.
6
Molecular phylogeny of the Pseudallescheria boydii species complex: proposal of two new species.
J Clin Microbiol. 2005 Oct;43(10):4930-42. doi: 10.1128/JCM.43.10.4930-4942.2005.
7
Micafungin: pharmacology, experimental therapeutics and clinical applications.
Expert Opin Investig Drugs. 2005 Apr;14(4):489-509. doi: 10.1517/13543784.14.4.489.
8
[Case report: a Fusarium fungaemia].
Mikrobiyol Bul. 2004 Jul;38(3):265-71.
9
In vitro interactions of licensed and novel antifungal drugs against Fusarium spp.
Diagn Microbiol Infect Dis. 2004 Jan;48(1):69-71. doi: 10.1016/j.diagmicrobio.2003.09.003.
10
Human fusariosis.
Clin Microbiol Infect. 2004 Mar;10 Suppl 1:67-75. doi: 10.1111/j.1470-9465.2004.00845.x.
Zotero 插件